Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of Clinical …, 2018 - ascopubs.org
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of Clinical …, 2018 - snucm.elsevierpure.com
The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts of
treatmentnaïve patients to examine clinical activity and safety of osimertinib (an epidermal …
treatmentnaïve patients to examine clinical activity and safety of osimertinib (an epidermal …
[PDF][PDF] Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee, T Kurata… - J Clin Oncol, 2017 - academia.edu
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatmentnaıve patients to examine clinical activity and safety of osimertinib (an epidermal …
of treatmentnaıve patients to examine clinical activity and safety of osimertinib (an epidermal …
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of Clinical …, 2018 - s-space.snu.ac.kr
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naive patients to examine clinical activity and safety of osimertinib (an …
of treatment-naive patients to examine clinical activity and safety of osimertinib (an …
[PDF][PDF] Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee, T Kurata… - J Clin …, 2017 - clf1.medpagetoday.com
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatmentnaıve patients to examine clinical activity and safety of osimertinib (an epidermal …
of treatmentnaıve patients to examine clinical activity and safety of osimertinib (an epidermal …
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
SS Ramalingam, JCH Yang, CK Lee, T John, T Kurata… - 2018 - ahro.austin.org.au
Purpose The Osimertinib First Time in Patients Ascending Dose (AURA) study
(ClinicalTrials. gov identifier: NCT01802632) included two cohorts of treatment-naïve …
(ClinicalTrials. gov identifier: NCT01802632) included two cohorts of treatment-naïve …
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee, T Kurata… - Journal of Clinical …, 2018 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> The AURA study (ClinicalTrials. gov
identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine …
identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine …
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
SS Ramalingam, JC Yang, CK Lee… - Journal of Clinical …, 2017 - europepmc.org
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …